Posted by Michael Wonder on 21 Jul 2021
Drug Utilisation Subcommittee outcome statement
21 July 2021 - The outcome statement from the June 2021 Drug Utilisation Subcommittee meeting is now available.
The Drug Utilisation Subcommittee of the PBAC held its 102nd meeting on the 3 – 4 June 2021.
DUSC reviewed the utilisation of the following PBS medicines:
- Evolocumab for heterozygous familial hypercholesterolaemia
- Guanfacine hydrochloride for attention deficit hyperactivity disorder
- Somatropin for growth hormone deficiency
Read DUSC outcome statement